Additional Countries and rights to commercialize EPI-HNE in the Field of Use *************** outside the Territory *************** Dyax shall grant Debio a *************** to such other countries. Dyax will *************** to Debio of *************** (***************). Debio shall *************** after the *************** during which ***************. If Debio ***************, Dyax shall *************** and to ***************. Before *************** with ***************, Dyax ***************.
Additional Countries. CANADA UNITED STATES (U.S.)
Additional Countries. The parties may, by mutual written agreement, amend Schedule 2 from time to time during the term of this Agreement to add additional countries to the list of Protection Countries as (i) ALRT applies for protection in such additional countries, and (ii) needed by the parties for commercialization of Products. In the event that PARI proposes that one or more countries be added to the list of Protection Countries in Schedule 2 and ALRT fails or refuses to agree to the addition of the country(ies) proposed by PARI within thirty (30) days of its receipt of such proposal, then PARI shall have the right to require ALRT to apply for, seek issuance of, and maintain Patent Rights in such country(ies) at PARI’s expense, and ALRT shall promptly comply with the foregoing. In all cases, the license and rights granted to PARI hereunder shall include the rights to all such additional country(ies).
Additional Countries. Intact and New Company agree that they will have further discussions in good faith for the opportunity of New Company to market the Product in Vietnam, and Taiwan, or other countries, where Allied has sales channels.
Additional Countries. KEYSTONE DENTAL will initially have the exclusive license and right to distribute the Licensed Product in the Field of Use in the United States, Canada, Chile and all countries within the European Union. In the case of sales in any other country (other than Korea) where it seeks to register the Licensed Product, KEYSTONE DENTAL shall obtain the exclusive right from NIBEC based on the agreement between NIBEC and KEYSTONE DENTAL as well as subject to the following conditions
(i) NIBEC has not previously granted the distribution and license rights for the Licensed Product to a third party for the Field of Use in the applicable country; provided, however, that NIBEC shall not grant distribution and license rights to the Licensed Product to any third Party for the Field of Use in any other countries outside the Territory and Korea without first offering such distribution and license rights to KEYSTONE DENTAL in good faith; and
(ii) NIBEC and KEYSTONE DENTAL agree to an amendment to this Agreement regarding development of the Licensed Product in the country and establish a sales target which KEYSTONE DENTAL would be required to meet in order to maintain the exclusive distribution and license rights in the country.
Additional Countries. Should Licensee wish to register the Product for sale in countries other than [*], then [*]. Should licensee wish to register the Product in [*] the parties shall [*].
Additional Countries. Company shall have the right during the Software -------------------- Period, to notify Cerner in writing of its intent to expand the Territory to Additional Countries. Within ten (10) business days or receipt of such notice, Cerner shall respond in writing indicating either that (a) the Territory has been deemed to be expanded to include the Additional Country or (b) the inclusion of such Additional Country in the Territory at the time of such request would cause Cerner to be in breach of pre-existing contractual commitments (and subject to applicable confidentiality restrictions, Cerner shall inform Company as to the nature of such commitments). If during the Software Period, the Territory is expanded to include Additional Countries, Cerner shall have the option to eliminate any Additional Country from the Territory twenty-four months from the date such Additional Country was included in the Territory if Company fails to enter into a written agreement with another party to deliver Services in such Additional Country during such twenty-four month period.
Additional Countries. Miltenyi acknowledges that Bellicum and/or its Licensees may from time to time desire to use Miltenyi Products in one or more countries that are currently not part of the Designated Countries (each, an “Additional Country”). The Parties agree, upon reasonable written request by Bellicum from time to time during the term of this Agreement, to evaluate the regulatory requirements for utilizing of Miltenyi Products for manufacture of Bellicum Products in the requested Additional Country(ies). Based on the assessment of potentially required additional work (“Additional Work”), including but not limited to regulatory work pursuant to Section 4.9 as may be required to prepare and file Master Files for Miltenyi Products in support of Bellicum Product filings in such Additional Country(ies), the Parties will negotiate in good faith with the goal of entering into an agreement on mutually acceptable terms with respect to Miltenyi’s provision of such Additional Work. Bellicum shall inform Miltenyi in writing at least twelve (12) months in advance prior to any intended regulatory filing in an Additional Country.
Additional Countries. In the event that [***] wish a patent application within Neurocrine Patent Rights to be filed, prosecuted or maintained in a particular country additional to those countries indicated by [***], then the costs of such filing, prosecution and maintenance in respect of that application in that country shall be borne [***], and [***]. [***] will also have the right to indicate that it no longer wishes to bear the costs for outside counsel to prepare, file, prosecute, and maintain any aspect of Neurocrine Patent Rights and shall give [***] sufficient notice and opportunity to bear such costs, in which event [***].
Additional Countries. If exclusive sublicense rights to the Novartis Patents become available in ******, then MIP shall notify BIOMEDICA in writing of the existence of such rights, and the Parties shall undertake to include ****** within the Territory under this Agreement. Other than ******, if after the Effective Date but within the Term of this Agreement, if MIP desires to sublicense rights to the Novartis Patents for any country not included in the Territory, then MIP shall give BIOMEDICA reasonable notice of its intent and an opportunity to participate in negotiations for sublicense rights in such country.
